Early end-of-life talks can reduce aggressive cancer care

This article originally appeared here.
Share this content:
Early End-of-Life Talks Can Reduce Aggressive Cancer Care
Early End-of-Life Talks Can Reduce Aggressive Cancer Care

(HealthDay News) -- For stage IV cancer patients, end-of-life (EOL) discussions that are conducted with physicians before the last 30 days of life correlate with less aggressive care close to death and greater use of hospice care, according to a study published online Nov. 13 in the Journal of Clinical Oncology.

In order to assess the correlation between EOL characteristics and the aggressiveness of care that patients receive near death, Jennifer W. Mack, M.D., M.P.H., of the Dana-Farber Cancer Institute in Boston, and colleagues conducted a prospective cohort study involving 1,231 patients with stage IV lung or colorectal cancer who survived at least one month but died during a 15-month study period.

The researchers found that nearly half of patients received one or more markers of aggressive EOL care, including 16 percent who received chemotherapy within the last 14 days of life; 9 percent who received care in the intensive care unit in the last 30 days of life; and 40 percent who received acute hospital-based care in the last 30 days of life. The likelihood of receiving aggressive measures of care (chemotherapy, acute care, any aggressive care) at EOL was significantly lower for those patients who had EOL discussions with their physicians before the last 30 days of life. These patients also had a significantly increased likelihood of receiving hospice care and initiating hospice care earlier.

"Given the many arguments for less aggressive EOL care, earlier discussions have the potential to change the way EOL care is delivered for patients with advanced cancer and help to assure that care is consistent with patients' preferences," the authors write.

Full Text

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs